纳武利尤单抗治疗异基因移植后复发血液系统恶性肿瘤的多中心1期研究
这项多中心、研究者发起的1期试验评估纳武利尤单抗治疗异基因造血细胞移植(alloHCT)后复发血液系统恶性肿瘤的最大耐受剂量与安全性。28例患者接受治疗,1 mg/kg组6例中2例出现剂量限制性毒性,0.5 mg/kg组22例中4例出现剂量限制性毒性(含2例致命性移植物抗宿主病)。可评估患者总缓解率为32%(8/25),中位随访11个月时1年无进展生存率和总生存率分别为23%和56%。
要点
- 1 mg/kg组6例中2例出现免疫相关不良事件所致剂量限制性毒性。
- 0.5 mg/kg组22例中4例出现剂量限制性毒性,包括2例免疫相关不良事件和2例致命性移植物抗宿主病。
- 可评估患者总缓解率为32%(8/25),抗肿瘤活性有限。
核心结论
- 纳武利尤单抗用于alloHCT后复发血液系统恶性肿瘤时出现移植物抗宿主病和免疫相关不良事件,需下调剂量,抗肿瘤活性有限。
- 作者认为,alloHCT后抗PD-1治疗的进一步研究可能需要特定的毒性缓解策略。
研究设计与样本
- 多中心、研究者发起的1期前瞻性临床试验(NCT01822509),主要目标为确定最大耐受剂量和安全性,次要目标为评估疗效和免疫学活性。
- 纳入alloHCT后复发血液系统恶性肿瘤患者,共28例接受治疗(髓系19例,淋系9例)。
- 纳武利尤单抗每2周给药直至疾病进展或不可接受毒性,从1 mg/kg队列开始,按毒性计划降至0.5 mg/kg队列。
主要发现
- 患者中位年龄57岁(范围27-76),alloHCT至入组中位时间21个月(范围5.6-108.5)。
- 1 mg/kg组6例中2例出现免疫相关不良事件所致剂量限制性毒性。
- 0.5 mg/kg组22例中4例出现剂量限制性毒性,包括2例免疫相关不良事件和2例致命性移植物抗宿主病。
- 可评估疗效患者总缓解率为32%(8/25)。
- 中位随访11个月时,1年无进展生存率为23%,1年总生存率为56%。
关键数值与推荐
- 1 mg/kg队列6例中2例出现剂量限制性毒性。
- 0.5 mg/kg队列22例中4例出现剂量限制性毒性,其中2例为免疫相关不良事件、2例为致命性移植物抗宿主病。
- 可评估患者总缓解率为32%(8/25)。
- 中位随访11个月,1年无进展生存率23%、1年总生存率56%。
临床怎么用
- 作者认为,alloHCT后抗PD-1治疗的进一步研究可能需要特定的毒性缓解策略。
局限性
- 原文报告了致命性移植物抗宿主病和免疫相关不良事件等毒性,并因此下调剂量。
- 作者在结论中指出抗肿瘤活性有限,并认为进一步研究可能需要特定的毒性缓解策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs-tumor effects following allogeneic hematopoietic cell transplantation (alloHCT), but retrospective studies of anti-PD-1 therapy reported substantial toxicity from graft-versus-host-disease (GVHD). Here, we report the results of a prospective clinical trial of PD-1 blockade for relapsed hematologic malignancies (HMs) after alloHCT (NCT01822509). The primary objective in this phase 1 multicenter, investigator-initiated study was to determine maximum tolerated dose and safety. Secondary objectives were to assess efficacy and immunologic activity. Patients with relapsed HMs following alloHCT were eligible. Nivolumab was administered every 2 weeks until progression or unacceptable toxicity, starting with a 1-mg/kg cohort, with planned deescalation based on toxicity to a 0.5-mg/kg cohort. Twenty-eight patients were treated (n = 19 myeloid, n = 9 lymphoid). Median age was 57 years (range 27-76), and median time from alloHCT to enrollment was 21 months (range 5.6-108.5). Two of 6 patients treated at 1 mg/kg experienced dose-limiting toxicity (DLT) from immune-related adverse events (irAEs). Twenty-two patients were treated at 0.5 mg/kg, and 4 DLTs occurred, including 2 irAEs and 2 with fatal GVHD. The overall response rate in efficacy-evaluable patients was 32% (8/25). With a median follow-up of 11 months, the 1-year progression-free survival and overall survival were 23% and 56%, respectively. In this first prospective clinical trial of an anti-PD-1 antibody for post-alloHCT relapse, GVHD and irAEs occurred, requiring dose deescalation, with only modest antitumor activity. Further studies of anti-PD-1 therapy post-alloHCT may require specific toxicity mitigation strategies. This trial was registered at www.clinicaltrials.gov as #NCT01822509.
引用
- Davids MS, Kim HT, Costello C, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020. PMID: 32478814. doi:10.1182/blood.2019004710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。